Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Raymond F. Anton, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT00183196
First received: September 13, 2005
Last updated: April 23, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to determine whether, after a period of abstinence, adding 6 weeks of gabapentin (a medication approved to treat seizures) to a standard 16-week naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) treatment protocol is helpful in decreasing relapse to drinking compared to naltrexone alone or placebo. All participants will receive alcohol counseling.


Condition Intervention Phase
Alcohol Dependence
Drug: Naltrexone
Drug: Naltrexone plus Gabapentin
Other: Inactive Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Gabapentin as an Adjunct to Naltrexone for Alcoholism

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Time to Relapse to Drinking [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Time to relapse drinking which is 5 standard drinks for males and 4 standard drinks for females. Subjects had a minimum of 4 days of abstinence prior to being entered into the protocol.


Enrollment: 150
Study Start Date: January 2003
Study Completion Date: June 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Naltrexone plus placebo
Drug: Naltrexone
Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
Active Comparator: 2
naltrexone + gabapentin
Drug: Naltrexone plus Gabapentin
naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
Sham Comparator: 3
Placebo plus placebo
Other: Inactive Placebo
Placebo

Detailed Description:

Subjects will enter the trial after maintaining 4 days of abstinence. During this period multiple assessments will be collected. After entering the double blind treatment portion of the study, they will be evaluated weekly for the first month, then bi-weekly until week 12 and again at week 16. There will be two follow-up visits at weeks 28 and 40. Urinary riboflavin and pill counts will be utilized to determine compliance with the medication regime.

Comparison(s): Naltrexone (50 mg/day) alone for 16-weeks; naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks, or inactive placebos. All subjects will receive up to 20 sessions of individual alcohol counseling.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet criteria for primary alcohol dependence including loss of control of drinking
  • No more than one previous inpatient medical detoxification
  • Consumes on average 5 standard drinks for men and 4 standard drinks for women
  • Able to maintain sobriety for 4 days (with or without detox medications).
  • Able to read and understand questionnaires and Informed Consent
  • Lives within 50 miles of the study site

Exclusion Criteria:

  • Currently meets DSM-IV criteria for any other psychoactive substance dependency disorder except nicotine dependence
  • Ever abused opiates
  • Any psychoactive substance abuse, except marijuana and nicotine within the last 30 days as evidenced by subject report, collateral report, or urine drug screen.
  • Meets DSM-IV criteria for current Axis I disorder of major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, dissociative disorder or eating disorder, schizophrenia, or any other psychotic disorder or organic mental disorder.
  • Has current suicidal or homicidal ideation
  • Need for maintenance or acute treatment with any psychoactive medication including antiseizure medications.
  • Current use of disulfiram.
  • Clinically significant medical problems, such as cardiovascular, renal, GI or endocrine problem that would impair participation or limit medication ingestion.
  • Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days of abstinence.
  • Sexually active females of child bearing potential who are pregnant (by urine HCG), nursing or who are not using a reliable form of birth control.
  • Has current charges pending for a violent crime (not including DUI related offenses).
  • Does not have a stable living situation and a reliable source of collateral reporting.
  • Has taken an opiate antagonist drug in the last month.
  • Has taken gabapentin in the last month or has experienced adverse effects from it at any time in the past.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00183196

Locations
United States, South Carolina
Medical University of South Carolina, Center for Drug and Alcohol Programs
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Raymond F. Anton, MD Medical University of South Carolina
  More Information

Publications:
Responsible Party: Raymond F. Anton, Distinguished University Professor, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00183196     History of Changes
Other Study ID Numbers: NIAAAANT09568-2005a, 5R01AA009568-14, NIH RO1 AA09568
Study First Received: September 13, 2005
Results First Received: November 20, 2012
Last Updated: April 23, 2013
Health Authority: United States: Federal Government

Keywords provided by Medical University of South Carolina:
Alcohol dependence
Alcoholism
Heavy drinking

Additional relevant MeSH terms:
Alcoholism
Alcohol-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Gabapentin
Naltrexone
Analgesics
Anti-Anxiety Agents
Anti-Dyskinesia Agents
Anticonvulsants
Antimanic Agents
Antiparkinson Agents
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Narcotic Antagonists
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on October 29, 2014